Development of Triple-negative breast cancer (TNBC) syngeneic models and TROP2-directed antibody-drug conjugate (ADC) surrogate to model therapeutic combinations

被引：0
|
作者：
Chou, Chih-Chien
Kardos, Jordan
Yang, Becky
Orf, Jessica
Dave, Rutwij
Lai, Yurong
Lee, Chingwei V.
Papalia, Giuseppe A.
Boyd, Kelli
Diehl, Lauri
Scholler, Nathalie
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-07-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-07-12
引用
收藏
页数：3
相关论文
共 50 条
  • [41] METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC)
    Vahdat, L. T.
    Forero-Torres, A.
    Schmid, P.
    Blackwell, K.
    Telli, M. L.
    Melisko, M.
    Holgado, E.
    Moebus, V.
    Cortes, J.
    Fehrenbacher, L.
    Montero, A. J.
    Ma, C.
    Nanda, R.
    Wright, G. S.
    He, Y.
    Bagley, R. G.
    Halim, A.
    Turner, C. D.
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [42] Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
    Shastry, Mythili
    Jacob, Saya
    Rugo, Hope S.
    Hamilton, Erika
    BREAST, 2022, 66 : 169 - 177
  • [43] Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
    Si, Yingnan
    Zhang, Ya
    Guan, Jia-Shiung
    Ngo, Hanh Giai
    Totoro, Angela
    Singh, Ajeet Pal
    Chen, Kai
    Xu, Yuanxin
    Yang, Eddy S.
    Zhou, Lufang
    Liu, Runhua
    Liu, Xiaoguang
    VACCINES, 2021, 9 (08)
  • [44] Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates
    Dalenc, Florence
    Sarradin, Victor
    Nicolai, Vincent
    Franchet, Camille
    Ung, Mony
    BULLETIN DU CANCER, 2021, 108 (01) : 67 - 79
  • [45] METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)
    Schmid, P.
    Melisko, M.
    Yardley, D. A.
    Blackwell, K.
    Forero, A.
    Ouellette, G.
    He, Y.
    Bagley, R. G.
    Zhang, J.
    Vahdat, L. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
    Bardia, A.
    Spring, L. M.
    Juric, D.
    Partridge, A.
    Ligibel, J.
    Kuter, I.
    Peppercorn, J.
    Parsons, H.
    Ryan, P.
    Chawla, D.
    Attaya, V.
    Fitzgerald, D. M.
    Viscosi, E.
    Lormill, B.
    Shellock, M.
    Moy, B.
    Tolaney, S. M.
    Ellisen, L. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S394 - S394
  • [47] Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
    Modi, Shanu
    Pusztai, Lajos
    Forero, Andres
    Mita, Monica
    Miller, Kathy D.
    Weise, Amy
    Krop, Ian
    Burris, Howard, III
    Kalinsky, Kevin
    Tsai, Michaela
    Liu, Minetta C.
    Hurvitz, Sara A.
    Wilks, Sharon
    Ademuyiwa, Foluso
    Diab, Sami
    Han, Hyo S.
    Kato, Giraldo
    Nanda, Rita
    O'Shaughnessy, Joyce
    Kostic, Ana
    Li, Martha
    Specht, Jennifer
    CANCER RESEARCH, 2018, 78 (04)
  • [48] METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC).
    Yardley, Denise A.
    Melisko, Michelle E.
    Forero, Andres
    Daniel, Brooke R.
    Montero, Alberto J.
    Guthrie, Troy H.
    Canfield, Vikki A.
    Oakman, Catherine Angela
    Chew, Helen K.
    Ferrario, Cristiano
    Volas-Redd, Gena H.
    Young, Robyn R.
    Henry, Norah Lynn
    Aneiro, Lynn
    He, Yi
    Turner, Christopher D.
    Davis, Thomas A.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts
    Yao, Sufei
    Shang, Chengzhang
    An, Gao
    Guo, Chaoshe
    An, W. Frk
    Yang, Yi
    CANCER RESEARCH, 2024, 84 (06)
  • [50] Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
    Goldenberg, David M.
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Rossi, Edmund A.
    Sharkey, Robert M.
    ONCOTARGET, 2015, 6 (26) : 22496 - 22512
12345